Monitor the compliance plan submission deadline of October 21, 2026, and NYSE American's acceptance. The company's ability to raise additional capital or execute a reverse stock split to boost equity will be critical. Failure to submit an acceptable plan could trigger immediate delisting proceedings.
Price Chart
Executive Summary
Calidi Biotherapeutics received a delisting notice from NYSE American on September 21, 2026, for failing to meet the $4.0 million stockholders' equity continued listing standard (reported equity of $3.1 million as of June 30, 2026). The company has until October 21, 2026, to submit a compliance plan and until March 21, 2028, to regain compliance, or delisting proceedings will commence. This follows a $1.2 million dilutive offering just 8 days prior, highlighting severe financial distress.
Key Facts
- NYSE American notified Calidi on September 21, 2026, of non-compliance with Section 1003(a)(ii) requiring stockholders' equity of at least $4.0 million.
- Reported stockholders' equity was $3.1 million as of June 30, 2026, with net losses in three of the four most recent fiscal years.
- Company must submit a compliance plan by October 21, 2026, and regain compliance by March 21, 2028, or face delisting.
- Common stock continues trading under symbol CLDI with a '.BC' indicator added for below-compliance status.
- This filing follows a $1.2 million direct offering at $1.17 per share completed on September 17, 2026, just 8 days prior.
Financial Impact
Stockholders' equity deficiency of $0.9 million below the $4.0 million threshold; $1.2 million raised in recent offering may not be sufficient to regain compliance.
Risk Factors
- Delisting risk if compliance plan is not submitted by October 21, 2026, or not accepted by NYSE American.
- Inability to raise sufficient capital to increase stockholders' equity above $4.0 million by March 21, 2028.
- Continued trading with '.BC' indicator may deter institutional investors and reduce liquidity.
- Recent dilutive offering at $1.17 per share signals ongoing cash burn and limited financing options.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-044381 |
| Exhibit: ex99-1.htm | 0001493152-26-044381 |
| Document: 0001493152-26-044381-index-headers.html | 0001493152-26-044381 |
| Document: 0001493152-26-044381-index.html | 0001493152-26-044381 |
| Document: 0001493152-26-044381.txt | 0001493152-26-044381 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 25, 2026 4w ago | 8-K | $1.07 | awaiting T+20 | — | $0.6450 (+39.72%) |
Sep 22, 2026 4w ago | 8-K | $1.09 $0.7680 | ▲ +29.54% | ▲ +30.23% | $0.6450 (+40.83%) |
Sep 17, 2026 5w ago | 424B5 | $1.10 $0.8370 | ▲ +23.91% | ▲ +24.11% | $0.6450 (+41.36%) |
Aug 13, 2026 10w ago | 8-K | $1.59 $1.22 | ▼ −23.27% | ▼ −21.28% | $0.6450 (−59.43%) |
Aug 13, 2026 10w ago | Press Release | $1.59 $1.22 | ▼ −23.27% | ▼ −21.28% | $0.6450 (−59.43%) |
Jun 29, 2026 16w ago | 3 | $0.1700 $0.0933 | ▼ −45.12% | ▼ −42.80% | $0.6450 (+279.41%) |
May 26, 2026 21w ago | Press Release | $2.83 $2.51 | ▼ −11.30% | ▼ −9.24% | $0.6450 (−77.22%) |
May 22, 2026 22w ago | Press Release | $2.83 $2.51 | ▲ +11.30% | ▲ +9.24% | $0.6450 (+77.22%) |
Apr 20, 2026 27w ago | Press Release | $0.2500 $0.1830 | ▼ −26.80% | ▼ −31.00% | $0.6450 (+158.00%) |
Mar 27, 2026 30w ago | Press Release | $0.2390 $0.2240 | ▼ −6.28% | ▼ −18.87% | $0.6450 (+169.87%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers